Summary of Key Information:

Reporting Period (Quarter/Year): Quarter and half year ended 30th September, 2026

Nature of Filing / Announcement: Outcome of Board Meeting

Audit Opinion:

Limited Review Report by Statutory Auditors - Nothing has come to our attention that causes us to believe that the accompanying Statement contains any material misstatement. [Clean Opinion]

Key Financial Highlights [Rs. in Lakhs]:

Standalone Results:

Quarter Ended 30.09.2026:

  • Revenue from Operations: ₹2,628.57 (vs. ₹1,931.00 in Q2 FY25 - 36% increase YoY)
  • Total Income: ₹2,736.27
  • Net Profit: ₹10.60 (vs. ₹326.36 in Q2 FY25 - 97% decrease YoY)
  • EPS - Basic: ₹0.02 (vs. ₹0.59 in Q2 FY25)
  • EPS - Diluted: ₹0.02 (vs. ₹0.59 in Q2 FY25)

Half Year Ended 30.09.2026:

  • Revenue from Operations: ₹4,186.94 (vs. ₹3,601.82 in H1 FY25 - 16% increase YoY)
  • Total Income: ₹4,386.26
  • Net Loss: ₹(114.72) (vs. profit of ₹345.85 in H1 FY25)
  • EPS - Basic: ₹(0.21) (vs. ₹0.63 in H1 FY25)
  • EPS - Diluted: ₹(0.21) (vs. ₹0.63 in H1 FY25)

Standalone Balance Sheet as at 30.09.2026:

  • Property, Plant and Equipment: ₹4,195.34
  • Investments: ₹7,951.33
  • Trade Receivables: ₹5,780.64
  • Cash and Cash Equivalents: ₹247.68
  • Total Assets: ₹18,605.73
  • Equity Share Capital: ₹1,104.15
  • Other Equity: ₹12,081.26
  • Borrowings: ₹2,808.16 (Current) + ₹0.00 (Non-current)
  • Trade Payables: ₹1,808.40

Consolidated Results:

Quarter Ended 30.09.2026:

  • Revenue from Operations: ₹8,137.23
  • Total Income: ₹8,054.38
  • Net Profit: ₹115.02
  • EPS - Basic: ₹0.21
  • EPS - Diluted: ₹0.21

Half Year Ended 30.09.2026:

  • Revenue from Operations: ₹16,205.40
  • Total Income: ₹16,023.35
  • Net Profit: ₹244.76
  • EPS - Basic: ₹0.44
  • EPS - Diluted: ₹0.44

Consolidated Balance Sheet as at 30.09.2026:

  • Property, Plant and Equipment: ₹1,909.05
  • Goodwill: ₹3,307.71
  • Inventories: ₹9,250.98
  • Trade Receivables: ₹12,006.79
  • Cash and Cash Equivalents: ₹2,705.36
  • Total Assets: ₹34,139.75
  • Equity Share Capital: ₹1,104.15
  • Other Equity: ₹24,313.50
  • Borrowings: ₹2,808.16 (Current) + ₹2,155.87 (Non-current)
  • Trade Payables: ₹2,512.52

Segment-wise Performance:

The operating segment of the Group is identified as "Specialized Wholesale" as the Chief Operating Decision Maker reviews business performance at an overall level as one segment. Segment-wise disclosure is not applicable.

Corporate Actions:

Not Specified

Other Significant Information:

Pharmaceutical Formulation Plant at Jadcherla, Hyderabad:

  • Received WHO-GMP certification from CDSCO for the facility
  • Commercial production being progressively scaled up, initially catering to Angola and Dominican Republic markets
  • Successfully manufactured 22 different products so far
  • Total approved product portfolio: 34 products (initial 31 + 3 additional approvals)
  • Company continues to pursue further product approvals

Entities Included in Consolidation:

1. Balaxi Global FZCO, Dubai (Wholly owned subsidiary) including its subsidiaries:

  • Balaxi Healthcare Guatemala, S.A, Republic of Guatemala
  • Balaxi Healthcare Dominicana, S.R.L, Dominican Republic
  • Balaxi Healthcare, Honduras, S DE RL DE CV Honduras
  • Balaxi Healthcare Nicaragua
  • Balaxi Healthcare El Salvador SA DE EI Salvador
  • Balaxi Healthcare Angola Republic of Angola

2. Balaxi Healthcare Ecuador S.A.S (Wholly Owned Subsidiary)